SELLAS Life Sciences Group, Inc. financial data

Symbol
SLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
7 Times Square, Suite 2503, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
GALENA BIOPHARMA, INC. (to 12/15/2017), Galena Biopharma, Inc. (to 12/15/2017), RXI PHARMACEUTICALS CORP (to 9/21/2011)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 120 % +4.45%
Debt-to-equity 252 % -16.7%
Return On Assets -179 % +10.6%
Operating Margin -4.2K % -1160%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.4M shares +120%
Common Stock, Shares, Outstanding 64.4M shares +127%
Entity Public Float 44.4M USD -3.03%
Common Stock, Value, Issued 6K USD +100%
Weighted Average Number of Shares Outstanding, Basic 68.3M shares +141%
Weighted Average Number of Shares Outstanding, Diluted 68.3M shares +141%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Costs and Expenses 32.8M USD -16.3%
Operating Income (Loss) -32.8M USD +16.3%
Nonoperating Income (Expense) 492K USD +135%
Net Income (Loss) Attributable to Parent -32.3M USD +15.8%
Earnings Per Share, Basic -0.67 USD/shares +53.5%
Earnings Per Share, Diluted -0.67 USD/shares +53.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21M USD +430%
Accounts Receivable, after Allowance for Credit Loss, Current 1M USD
Assets, Current 24M USD +362%
Operating Lease, Right-of-Use Asset 513K USD -13.3%
Goodwill 1.91M USD 0%
Assets 26.5M USD +228%
Accounts Payable, Current 4.55M USD +4.77%
Employee-related Liabilities, Current 1.79M USD +15.6%
Accrued Liabilities, Current 5.49M USD -20.8%
Liabilities, Current 10.6M USD -9.56%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 10.6M USD -10.9%
Retained Earnings (Accumulated Deficit) -241M USD -15.4%
Stockholders' Equity Attributable to Parent 15.9M USD
Liabilities and Equity 26.5M USD +228%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8M USD +11.3%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +41%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 64.4M shares +127%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 15.9M USD +134%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.1M USD +419%
Deferred Tax Assets, Valuation Allowance 18.8M USD +15.2%
Deferred Tax Assets, Gross 19M USD +15%
Operating Lease, Liability 576K USD -10.6%
Lessee, Operating Lease, Liability, to be Paid 612K USD -7.97%
Operating Lease, Liability, Current 576K USD +23.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 477K USD -10.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 477K USD -10.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure -7.17%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36K USD +71.4%
Deferred Tax Assets, Operating Loss Carryforwards 12.2M USD +16.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Operating Lease, Payments 500K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 184K USD 0%
Share-based Payment Arrangement, Expense 1.69M USD -17.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%